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In multiple sclerosis, encephalitogenic CD4 + lymphocytes require adhesion molecules to accumulate into central nervous system inflammatory lesions. Using proteomic techniques, we identified expression of melanoma cell adhesion molecule (MCAM) on a subset of human effector memory CD4 + lymphocytes and on human blood-brain barrier endothelium. Herein, we demonstrate that MCAM is a stable surface marker that refines the identification of interleukin 17 + , interleukin 22 + , RAR-related orphan receptor and interleukin 23 receptor + cells within the CD161 + CCR6 + subset of memory CD4 + lymphocytes. We also show that MCAM + lymphocytes express significantly more granulocyte/macrophage colony stimulating factor and granzyme B than MCAM À lymphocytes. Furthermore, the proportion of MCAM + CD4 + lymphocytes is significantly increased in the blood and in the central nervous system of patients with multiple sclerosis and experimental autoimmune encephalomyelitis animals compared with healthy controls or other neurological diseases, and MCAM expression is upregulated at the blood-brain barrier within inflammatory lesions. Moreover, blockade of MCAM or depletion of MCAM + CD4 + T lymphocytes both restrict the
Introduction
Multiple sclerosis is a neuroinflammatory disorder characterized by immune cell infiltration into the CNS. In multiple sclerosis, multifocal immune infiltrates are associated with areas of demyelination, gliosis and axonal loss and are largely responsible for the recurrent clinical symptoms (Sospedra and Martin, 2005) . The nature of the immune cells responsible for CNS damage in multiple sclerosis is still a matter of debate. While T-bet-expressing T helper (T H ) 1 CD4 + T lymphocytes were originally incriminated as disease-inducing T lymphocytes (Yang et al., 2009) , RAR-related orphan receptor (ROR-, now known as RORC)-expressing T H 17 CD4 + lymphocytes have recently emerged as a highly inflammatory subset associated with multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis (EAE) (Langrish et al., 2005; Bettelli et al., 2006; Kebir et al., 2007 Kebir et al., , 2009 Tzartos et al., 2008; Korn et al., 2009) . T H 17 lymphocytes are more abundant in the peripheral blood and CSF of patients with multiple sclerosis (Matusevicius et al., 1999; Frisullo et al., 2008; Brucklacher-Waldert et al., 2009; Durelli et al., 2009; Alexander et al., 2010; Babaloo et al., 2010; Li et al., 2011) compared with controls, cross the blood-brain barrier more readily than T H 1 lymphocytes (Kebir et al., 2007) and have been associated with a higher disease burden in the brain (Stromnes et al., 2008) . T H 17 lymphocytes generated in the presence of IL23 express ROR-, interleukin (IL)17, IL22 and granulocyte/macrophage colony stimulating factor (GM-CSF) and display a great encephalitogenic potential in mouse, according to recent studies (Awasthi et al., 2009; Ghoreschi et al., 2010; Codarri et al., 2011; El-Behi et al., 2011; Hirota et al., 2011) .
To gain access to the CNS parenchyma, immune cells of the peripheral blood need to cross vascular barriers of the CNS. Under physiological conditions, the blood-brain barrier limits access of leukocytes to the CNS parenchyma, such that only a few leukocytes can enter and exert immune surveillance (Hickey, 2001; Mrass and Weninger, 2006) . Under inflammatory conditions, the interaction of blood-brain barrier endothelial cells with leukocytes via expression of cell adhesion molecules contributes to leukocyte transmigration in the CNS parenchyma, an early event in the development of CNS inflammation (Engelhardt, 2006; Mrass and Weninger, 2006; Man et al., 2007) . The importance of these blood-brain barrier-leukocyte interactions has been demonstrated by the clinical efficacy of 4 b 1 integrin blockade as a treatment for multiple sclerosis (Polman et al., 2006) . However, serious adverse events can arise because of the resulting restriction of immunosurveillance (Ransohoff, 2005) , which points to the need to identify molecules involved specifically in the recruitment of encephalitogenic immune cell populations through the blood-brain barrier.
Melanoma cell adhesion molecule (MCAM or CD146) is an adhesion molecule of the immunoglobulin superfamily (Sers et al., 1993) . MCAM is expressed by peripheral endothelial cells and by a discrete IL17-producing T cell population (Elshal et al., 2005; Brucklacher-Waldert et al., 2009; Dagur et al., 2011) . Although its exact role remains to be determined, MCAM can reportedly interact with itself (homotypic interaction) (Staquicini et al., 2008) and with a yet unidentified ligand (heterotypic interaction) (Bardin et al., 2009) . MCAM has been implicated in different melanoma-dependent processes such as tumour growth, invasiveness, metastasis, homotypic and heterotypic cell adhesion and increased matrix metalloproteinase activity (Xie et al., 1997; Mills et al., 2002; Bu et al., 2006) . More recently, MCAM was reported to be involved in the rolling, adhesion and migration of leukocytes across peripheral non-CNS endothelial cells (Guezguez et al., 2007; Bardin et al., 2009; Brucklacher-Waldert et al., 2009) and in vascular endothelial growth factor-induced angiogenesis (Zhuang et al., 2010) .
In the current manuscript, we demonstrate that MCAM is expressed by blood-brain barrier endothelial cells and by a highly inflammatory and disease-inducing subset of effector memory T lymphocytes. We show that MCAM is upregulated under inflammatory conditions both on blood-brain barrier endothelial cells and on T lymphocytes, is strongly associated with ROR-, IL23R, IL17, IL22, GM-CSF and granzyme B (GZMB) expression by CD4 + lymphocytes and is more abundant in the peripheral blood and CSF of patients with multiple sclerosis, compared with healthy controls. Moreover, MCAM modulation in vivo restricts the adhesion and migration of T H 17 lymphocytes and has a significant impact on the clinical and pathological severity of EAE. Therefore, our data identify MCAM as a potential biomarker for multiple sclerosis and as a valuable therapeutic target for the treatment of T lymphocyte-dependent CNS inflammation, as occurs in patients with multiple sclerosis.
Materials and methods

Blood-brain barrier endothelial cell isolation and culture
Blood-brain barrier endothelial cells were isolated from non-epileptic surgical human CNS material (resection path) according to a previously published protocol (Ifergan et al., 2006; Kebir et al., 2007; Cayrol et al., 2008) . Informed consent and ethic approval were given prior to surgery (Centre de Recherche du Centre Hospitalier de l'Université de Montré al research ethic committee approval number HD04.046). Characterization and purity was performed as previously published.
Reverse transcription-polymerase chain reaction
RNA from blood-brain barrier endothelial cells and human umbilical vein endothelial cells was extracted with TRIzol Õ reagent (Invitrogen).
Reverse transcription reaction was performed using M-MLV reverse transcriptase (Invitrogen 
Western blot
Forty micrograms of blood-brain barrier endothelial cell lysate was analysed by standard SDS-PAGE (Wosik et al., 2007) using anti-MCAM (mouse monoclonal P1H12, 1:100, Chemicon). Specific binding was revealed with horseradish peroxidase conjugated anti-rabbit (1:1000, DakoCytomation) using the ECL system (Amersham Biosciences). b-actin (1:20 000, Sigma) was used as a loading control.
Human immune cell isolation, expansion and culture were isolated using the MACS Õ isolation columns (or when specified using fluorescence-activated cell sorting) either ex vivo or after culture as indicated, according to the manufacturer's protocol (Miltenyi).
Immune cell purity was assessed by flow cytometry using fluorochrome-labelled anti-CD14 (fluorescein isothiocyanate), anti-CD45RO (phycoerythrin), anti-CD146 (allophycocyanin), anti-CD3 (A700) and anti-CD4 (phycoerythrin-Cy7) (all antibodies from BD Pharmingen except anti-CD146 from Miltenyi Biotec clone 541-10B2) and was routinely 495%. CD4 + CD45RO + lymphocytes were labelled when necessary with the vital dye 5,6-carboxyfluorescein diacetate succinimidyl ester as previously described (Stromnes et al., 2008) . T lymphocytes were cultured as previously published (Kebir et al., 2007) . Briefly 0.5 Â 10 6 cells/ml were cultured with either autologous monocytes at a 1:0.6 ratio and soluble anti-CD3 (eBioscience, clone OKT3, 2.5 mg/ ml), or with plate-bound anti-CD3 (2.5 mg/ml incubated 24 h at 4 C) and soluble anti-CD28 (BD Pharmingen, 2 mg/ml) in X-VIVO TM 15 medium (Lonza) without serum and supplemented with 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (Sigma). For T H 17 differentiation recombinant human IL23 (25 ng/ml), anti-human IL4 antibody (5 mg/ml) and anti-human interferon-gamma (IFN) antibody (5 mg/ml) were added, whereas IL12 (10 ng/ml) in the presence of anti-IL4 was added for T H 1 differentiation, IL4 (200 ng/ml) in the presence of anti-IFN and anti-IL12 antibodies (5 mg/ml) for T H 2 differentiation and IL2 (20 U/ml) in the presence of anti-IL4 and anti-IFN antibodies was added for non-specific stimulation and cells were harvested at Day 6 if not specified otherwise (all reagents from R&D Systems). To study the influence of cytokines on MCAM expression assay, CD4 + CD45RO + MCAM À lymphocytes were cultured with plate-bound anti-CD3 and soluble anti-CD28 and only the specified cytokine was added daily: recombinant human IL2 (20 U/ml), recombinant human IL17 (100 ng/ml), recombinant human GM-CSF (20 ng/ml, BD Biosciences), recombinant human IL12 (20 ng/ml, R&D Systems), tumour necrosis factor (TNF; 10 U/ml), IFN (10 U/ml), IL1b (10 ng/ml) or recombinant human IL23 (25 ng/ml), or Phosphate Buffered Saline (PBS) for 6 days. and macrophages were generated from D7 adherent CD14 + cells cultured in 10%
human serum supplemented medium refreshed every other day. After in vitro culture, the proliferation of lymphocytes, the presence of activation markers and the capacity to produce cytokines were assessed by flow cytometry as previously described Kebir et al., 2009 
Patient classification
Patients were classified according to McDonald's revised criteria (Polman et al., 2005) as clinically isolated syndrome (n = 15 patients), relapsing-remitting multiple sclerosis (n = 60), primary progressive multiple sclerosis (n = 11), secondary progressive (n = 7), benign multiple sclerosis (Expanded Disability Status Scale 41.0 after 510 years of evolution; n = 4) or other neurological disease (n = 24) or healthy control (n = 28) by two certified neurologists from the Centre de Recherche du Centre Hospitalier de l'Université de Montré al multiple sclerosis clinic, blinded to the experiment results and with at least 6 months of follow-up after the samples were analysed for clinically isolated syndrome. Patients suffering from clinically isolated syndrome or relapsing-remitting multiple sclerosis were further classified as either untreated stable (53 months after clinically isolated syndrome clinical event or last relapse; untreated stable relapsing-remitting multiple sclerosis n = 27 and untreated stable clinically isolated syndrome n = 13) or untreated in 'relapse' (onset of clinically isolated syndrome or acute relapse 42 weeks; acute relapse relapsing-remitting multiple sclerosis = 7 and acute first 'relapse' as clinically isolated syndrome n = 2) or treated [currently on glatiramer acetate (nine patients) or b-interferon (14 patients) or high-dose corticosteroids (three patients) in the last month; relapsing-remitting multiple sclerosis on treatment n = 26]. Relapse was defined as acute/subacute onset of new neurological deficit lasting 448 h. Other neurological diseases included thunderclap headache without subarachnoid haemorrhage, leukoaraiosis, hydrocephalus, trigeminal neuralgia, tympanic hydrops, migraine and subjective sensory symptoms with normal neurological exam, MRI and CSF analysis.
Experimental autoimmune encephalomyelitis disease induction, scoring and pathology EAE was induced as previously described . Briefly, female C57BL/6 mice were immunized subcutaneously with 200 mg MOG 35 -55 (MEVGWYRSPFSRVVHLYRNGK; Sheldon Biotechnology Centre) in a 100 ml emulsion of incomplete Freund's adjuvant supplemented with 4 mg/ml Mycobacterium tuberculosis (Fisher Scientific). Pertussis toxin (500 ng, Sigma-Aldrich) was injected intraperitoneally on Days 0 and 2. Animals were then injected intraperitoneally on Days 2, 4, 6, 8 and 10 (prophylactic regimen) with either Fc-MCAM (gift from Elan, human Fc portion and mouse MCAM protein, 200 ml at 1 mg/ml, n = 10 animals per group) or isotype control (human IgG, Sigma, 200 ml at 1 mg/ml, n = 10) or vehicle (PBS, 200 ml, n = 10). As no difference in clinical scores or CNS pathology was detectable between isotype or vehicle control groups, PBS was used as control for the two subsequent pretreatment experiments. For the therapeutic regimen experiment, animals were injected intraperitoneally every other day starting at Day 11 (post-induction) with either Fc-MCAM (200 ml at 1 mg/ml, n = 9 animals) or isotype control (200 ml at 1 mg/ml, n = 8 animals). The scoring system used was as follows: 0 = normal; 1 = limp tail; 2 = slow righting-reflex; 3 = paralysis of one hindlimb (monoparalysis); 4 = paralysis of both hindlimbs (paraparalysis); and 5 = moribund (requires sacrifice). Mice were scored by an investigator blinded to the treatment group. On Day 15, two representative animals from each group of the pretreatment experiments were sacrificed and CNS organs, spleen and lymph nodes were recovered and either frozen or processed for cell isolation and flow cytometry analysis as previously described (Ifergan et al., 2011) . The spinal cords were stained with Luxol Fast Blue and haematoxylin and eosin as previously described (Wosik et al., 2007) . Meningeal and parenchymal inflammatory lesions were counted per spinal cord and brain section as described (Kalyvas and David, 2004) . Briefly, spinal cord (four levels: cervical, thoracic, lumbar and sacral) and brain sections were stained with Luxol Fast Blue and haematoxylin and eosin and inflammatory lesions were visually counted by an investigator blinded to the treatment group. Counts of CD4 + , MHCII + and F4/80 + immune cells among the 10 greatest infiltrates (out of four sections from cervical, thoracic, lumbar and sacral levels) were performed for two animals per group using immunofluorescence-stained spinal cord sections. All counts were performed by two investigators blinded to the treatment group. For in vitro reactivation of peripheral leukocytes, EAE animals were sacrificed at Day 9 post-immunization, spleen and lymph nodes were recovered and leucocytes were isolated and cultured with MOG , mouse IL23 (20 ng/ml), human TGF-b (5 ng/ml) and anti-IL4 and anti-IFN antibodies.
Experimental autoimmune encephalomyelitis transfer
Active EAE was induced as described above except for pertussis toxin (200 ng) injected intraperitoneally on Day 0 only. On Day 9, 30 mice were sacrificed and leukocytes were recovered from lymph nodes and spleens as previously described . Cells were reactivated for 96 h in RPMI supplemented with 10% foetal bovine serum, non-essential amino acids, HEPES and b-mercaptoethanol, in the presence of MOG (20 mg/ml), recombinant mouse IL23 (20 ng/ml), recombinant human TGF-b (4 ng/ml), recombinant mouse IL6 (20 ng/ ml) and anti-mouse IFN clone XMG1.2 (20 mg/ml). Cells were then harvested and a negative selection for CD4 T cells was performed (Miltenyi). The total fraction was then incubated in MACS Õ buffer only and ran over an LS column, while the MCAM-depleted fraction was incubated with anti-LSEC beads (Miltenyi) and ran over an LS column (positive selection for MCAM). The effluent was washed in Hank's Balanced Salt Solution and 10 million cells were injected intraperitoneally to the recipient female C57BL/6 animals. On Day 2 following transfer, recipient mice were injected intraperitoneally with a single pertussis toxin (200 ng) dose. The scoring system used was the same as described above. All procedures were approved by the University of Montreal Animal Care committee and followed guidelines of the Canadian Council on Animal Care.
Flow cytometry and intracellular staining
Blood-brain barrier endothelial cells treated with IFN and TNF (100 U/ml) were recovered in cold PBS and Ethylene Diamine Tetraacetic Acid (EDTA), and incubated with anti-ICAM1 (phycoerythrin), anti-VCAM1 (fluorescein isothiocyanate) (antibodies from BD Biosciences, clones HA58 and 51-10C9, respectively) or anti-MCAM.
For lymphocyte intracellular cytokine staining, cells were activated for 4 h 30 min unless specified otherwise with 1 mg/ml ionomycin and 20 ng/ml phorbol 12-myristate 13-acetate (PMA) in the presence of 2 mg/ml brefeldin A (all from Sigma). Cells were stained for surface antigens and were then fixed and permeabilized in 4% (w/v) paraformaldehyde with 0.1% (w/v) saponin in Hank's Balanced Salt Solution for 10 min at room temperature. Intracellular cytokine staining on human cells was performed as previously described ; briefly cells were incubated with antibodies specific for human IFN in A700 (BD Biosciences), IL17 in A488 (eBioscience), IL22 in phycoerythrin (R&D Systems), granzyme B in A700 (BD Biosciences), GM-CSF in phycoerythrin (BD Biosciences), IL4 in phycoerythrin (BD Biosciences) and IL2 in phycoerythrin (BD Biosciences) for 30 min on ice in PBS buffer containing 0.1% (w/v) saponin, 1% foetal bovine serum, 0.1% (w/v) NaN 3 , followed by two washes and resuspended in staining buffer [1% (v/v) foetal bovine serum, 0.1% (w/v) NaN 3 in PBS].
For mice cells, immune cells isolated from lymph nodes, spleen and CNS were labelled with surface markers CD3 (A700 or PerCpCy5.5) CD4 (fluorescein isothiocyanate), CD8 (phycoerythrin), CD45 (PerCpCy5.5) (all from BD Biosciences), CD127/IL7 receptor (PerCpCy5.5) from eBioscience and MCAM in fluorescein isothiocyanate or phycoerythrin (Miltenyi Biotec and BioLegend, clone ME-9F1). Intracellular cytokine staining included antibodies specific for mouse IL17 (phycoerythrin), GM-CSF (phycoerythrin) and IFN (allophycocyanin) (BD Biosciences). Appropriate fluorochrome-matched isotype antibodies were used to assess non-specific background staining. All cell staining was acquired on a BD LSR II (Becton Dickinson) and analysed using the BD FACSDiva software (BD Bioscience).
Tissue and immunostaining
Post-mortem frozen sections (n = 20) from brains of three patients with relapsing-remitting multiple sclerosis and four healthy controls (normal brain tissue from non-epileptic surgical human CNS material) were studied as previously described . Freshly frozen sections (n = 50) from EAE animals (n = 10) sacrificed at Day 15 and from age-matched healthy controls (n = 6 mice) were studied as previously described (Ifergan et al., 2006; Alvarez and Teale, 2008) .
Immunocytofluorescence was performed on frozen samples following cytospin of fluorescence activated cell sorted MCAM + and MCAM À memory CD4 + T lymphocytes in 25% glycerin, as previously described . Briefly, active multiple sclerosis and EAE lesions were identified by Luxol Fast Blue and haematoxylin and eosin staining and defined as areas of demyelination associated with intense perivascular immune cell infiltration. For immunohistofluorescence, sections were fixed in acetone for 10 min and then transferred to ethanol for 5 min, hydrated in PBS and blocked with 10% serum (from the same species that the fluorochrome conjugated antibodies were derived) for 30 min at room temperature. Sections were incubated at room temperature for 60 min with primary antibodies diluted in 3% species specific serum. Sections were washed seven times with PBS and 0.05% Tween 20 after antibody incubation. Secondary antibodies were incubated for 40 min at room temperature when necessary. Then, sections were mounted using gelvatol containing TO-PRO Õ -3 (Invitrogen, 1:300) when required. Negative controls using secondary antibodies alone were included in each experiment and found to be negative for staining. We used the following primary antibodies: rabbit anti-mouse and human MCAM (monoclonal, EPR3208 Abcam, 1:200), rabbit antihuman CAV1 (polyclonal, Santa Cruz Biotechnology, 1:75), mouse anti-human IL17 (monoclonal, R&D systems, 1:50), rat anti-mouse IL17 (monoclonal, BD Pharmingen, clone TC11-18H10, 1:30), rat anti-mouse and human ROR-(monoclonal, eBioscience, clone AFKJS-9, 1:10), mouse anti-mouse and human T-bet (monoclonalAlexa-647 conjugated, eBioscience, clone eBio4B10, 1:7.5), mouse anti-human CD4 (monoclonal, BD Pharmingen, clone RPA-T4), rat anti-mouse CD4 (monoclonal, BD Pharmingen, clone RM4-5, 1:70), rat anti-mouse MHCII (monoclonal, BD Pharmingen, clone 2G9, 1:30), rat anti-mouse F4/80 (monoclonal, BioLegend, clone BM8, 1:80), rabbit anti-laminin (polyclonal, Dako, 1:200). When appropriate, we used the following secondary antibodies, either donkey anti-rabbit Rhodamine Red TM -X (RRX) 1:500, goat anti-mouse Alexa Fluor Fluorescence was visualized and acquired in a Leica Confocal Microscope secondary progressive platform (Leica Microsystems). Imaging processing and analysis was done using LAS (Leica) and ImageJ (NIH) software.
Real-time quantitative polymerase chain reaction
For ex vivo quantitative PCR studies, isolated CD4 + CD45RO + were fluorescence-activated cell sorted using anti-CD146-APC antibody (Miltenyi), yielding purity over 99% (BD FACSAria fast-real-time PCR system (Applied Biosystems). Gene-specific messenger RNA was normalized compared to endogenous control (18 S).
Blood-brain barrier transmigration assay
A modified Boyden chamber assay was used to model the blood-brain barrier, as previously reported (Ifergan et al., 2006; Kebir et al., 2007; Cayrol et al., 2008) . Blood-brain barrier endothelial cells (3 Â 10 4 ) were grown on gelatin-coated 3 -mm pore size Boyden chambers (Collaborative Biomedical Products) in culture media supplemented with 40% astrocyte-conditioned media for 72 h (to confluency). When indicated, antibodies specific for MCAM (P1H12, custom made, Chemicon, 40 mg/ml) or the appropriate isotype control (mouse IgG1, custom made, Chemicon, 40 mg/ml) were added 1 h prior to immune cell migration. A suspension of 1 Â 10 6 Day 6 T H 17 lymphocytes was added to the upper chamber and allowed to migrate for 18 h. Absolute number of cells that transmigrated to the lower chamber was then assessed. All conditions were performed in triplicate for each donor. To assess migration of MCAM + and MCAM À lymphocytes, Day 6 T H 17 lymphocytes were collected and then separated in two groups: MCAM À fraction where T H 17 lymphocytes were depleted from MCAM using anti-CD146 magnetic beads as described (mean purity over 95% as assessed by fluorescence-activated cell sorting) and MCAM + fraction where T H 17 lymphocytes were put through a magnetic column in the absence of magnetic beads (mean percentage of cells expressing MCAM $50%). Cell suspension was then added to the upper chamber as described.
Blood-brain barrier endothelial cell dynamic flow adhesion system
Flow system adhesion assay was performed as previously published (Ifergan et al., 2011) . Human blood-brain barrier endothelial cells (2 Â 10 5 cells/slide) were cultured on a 0.4 mm m-slide TM (Ibidi Integrated BioDiagnostics) in endothelial cell media in a final volume of 200 ml for 4 days to reach confluency. After 4 days, the m-slide TM was washed with fresh media and placed inside a live chamber (Live Chamber 37 C and 5% CO 2 ). The m-slide TM was connected to the flow system with a 50-cm long perfusion set tubing (aperture diameter of 0.8 mm) with a 90 angled connector. The flow generated by the Ibidi pump system was controlled through the Ibidi pump control software (Ibidi Integrated BioDiagnostics). For inflamed condition, endothelial cells were pretreated for 24 h with TNF/IFN 100 U/ml. Blood-brain barrier endothelial cells (inflamed or resting) were then treated with the isotype control (20 mg/ml) or anti-MCAM antibody (P1H12, 20 mg/ml) 1 h prior to the addition of T H 17 lymphocytes in a volume of 4 ml with a constant flow (applied air pressure: -370 Pa, flow rate: 0.43 ml/min, shear stress: 0.56 dyn/cm 2 , shear rate: 27 /s, cycle duration: 120 s, unidirectional flow). 5,6-Carboxyfluorescein diacetate succinimidyl ester-labelled in vitro cultured T H 17 lymphocytes (5 Â 10 6 ) pretreated for 1 h (20 mg/10 6 cells, P1H12 or isotype as indicated) at 4 C were then added to the flow system for a final volume of 5 ml. The cell velocity was evaluated using a Hamamatsu ORCA-ER digital camera combined with the Improvision Volocity software v5.5. Live time-lapse acquisition videos were recorded at constant intervals during 30 min. Cell velocity was automatically quantified and analysed from videos taken using different algorithms in Volocity software, removing clump cells and small debris based on their size and their basal fluorescence.
Statistical analyses
Statistical analyses were performed using PRISM Graphpad TM software and included ANOVA followed by Students' t-test or Bonferroni post-test, depending on the number of comparisons to controls. Only P-values 5 0.05 were considered statistically significant. Data are expressed as mean AE standard error of the mean (SEM).
Results
Melanoma cell adhesion molecule is expressed by human bloodbrain barrier endothelial cells and is upregulated in inflammatory conditions
MCAM was identified in a proteomic screen analysis of lipid raft membrane microdomains obtained from human blood-brain barrier endothelial cells grown in primary culture (Wosik et al., 2007; Cayrol et al., 2008) . We confirmed expression of MCAM in human brain endothelial cells by PCR, western blot, flow cytometry and immunocytofluorescence analysis (Fig. 1A-D) and in situ in the healthy human and mouse CNS ( Fig. 1E and Supplementary Fig. 3A ). We also found that treatment with TNF/IFN increases MCAM expression by blood-brain barrier endothelial cells (Fig. 1C and D) as occurs with ICAM-1 or VCAM. These data demonstrate that MCAM is expressed by brain endothelial cells and is upregulated in vitro with inflammatory cytokine treatment.
Melanoma cell adhesion molecule defines a unique subset of circulating human T lymphocytes expressing interleukin23R, ROR-, interleukin17, granulocyte/macrophage colony stimulating factor and granzyme B, in addition to interferon-and T-bet
Since MCAM is known to interact with itself, we then sought to investigate the expression of MCAM on peripheral blood mononuclear cells obtained from human healthy donors. As shown in Fig. 1F Supplementary Fig. 1A ). Conversely, expression of CD6, CD62L, CD27 and CCR7 is less frequent in the MCAM + population compared with the MCAM À population (Supplementary Fig. 1A ). Finally, while MCAM is also expressed by a small percentage of CD3 + CD8 + T lymphocytes ex vivo (Fig. 1F) , it is barely detectable on the surface of ex vivo CD19 + B lymphocytes and CD14 + monocytes (Fig. 1F) , or on in vitro differentiated mature dendritic cells and macrophages ( Supplementary Fig. 1B ).
Longitudinal analysis (ex vivo) of CD3 + CD4 + T lymphocytes obtained from healthy controls (n = 4) demonstrated stable expression of MCAM, with a maximal individual variation of 1.3% over 2 years (Fig. 1G) Supplementary Fig. 1C ). This was confirmed by immunocytofluorescence staining of peripheral blood cells ex vivo ( Supplementary Fig. 1D ). significantly (P = 0.08) and levels of T-bet and IFN messenger RNA were similar in both populations (Fig. 1H) (Fig. 2C) . During IL23-driven polarization, we found the expression of IFN to be comparable between MCAM + and MCAM À subpopulations (Fig. 2D) , whereas the percentage of IL17-expressing cells is significantly and consistently higher in MCAM + CD4 + T lymphocytes than in MCAM À cells (Fig. 2E) . We further demonstrated that IL17A and ROR-messenger RNA levels are preferentially upregulated in MCAM + lymphocytes following CD4 + CD45RO + in vitro activation (Fig. 2F) . We next elected to study whether the expression of MCAM on the surface of activated human memory CD4 + T lymphocytes correlated with expression of other cytokines. While MCAM is found to be strongly associated with IL17 expression, it is also associated with expression of granzyme B, IL22 and GM-CSF ( Fig. 2G and Supplementary Fig. 1E ). In addition, lymphocytes co-expressing IL17 and either IFN, GM-CSF, IL22 or granzyme B, as well as co-expressing IL17, IFN and GM-CSF, are significantly more frequent among the MCAM + fraction (Supplementary Fig. 1E ).
Conversely, levels of IL4, IL2 and IFN are comparable between MCAM + and MCAM À populations ( Fig. 2G and Supplementary   Fig. 1E ), Moreover, similar results were obtained following in vitro activation of cells sorted according to surface expression of MCAM within the CD161 + CCR6 + population (Fig. 2H ). To confirm that MCAM expression is associated with activated CD4 + CD45RO + T lymphocytes, cell division was assessed. A significantly higher percentage of dividing cells is observed in MCAM + than in MCAM À lymphocytes following activation ( Supplementary Fig. 1F ). Taken together, our data identify MCAM as a stable cell surface marker which defines a subset of ROR--expressing and IL23-responsive human memory CD4 + T lymphocytes, which have the capacity to proliferate and to express the pro-inflammatory cytokines IL17, GM-CSF, granzyme B and IL22, in addition to IFN.
MCAM + lymphocytes are found in high proportions in peripheral blood, cerebrospinal fluid and in central nervous system lesions of patients with multiple sclerosis Since MCAM-expressing T lymphocytes can produce IL17 and GM-CSF, they may play a role in the pathogenesis of T H 17-mediated neuroinflammatory diseases such as multiple sclerosis. We therefore compared the expression of MCAM on ex vivo peripheral blood mononuclear cells obtained from patients with multiple sclerosis, healthy controls and subjects affected with other neurological diseases. The percentage of CD4 + T lymphocytes expressing MCAM is significantly increased in patients with relapsing-remitting multiple sclerosis and in patients with clinically isolated syndrome suggestive of multiple sclerosis, compared with healthy controls and subjects with other neurological diseases (Fig. 3A) . Moreover, the percentage of MCAM + CD4 + T lymphocytes is significantly higher during acute relapse compared with relapsing-remitting multiple sclerosis or clinically isolated syndrome in remission. Conversely, treatment of relapsing-remitting multiple sclerosis is associated with a trend toward a reduction in the percentage of MCAM-expressing CD4 T lymphocytes (P = 0.14; Fig. 3A Fig. 3B and C) . Finally, we found that MCAM + CD4 + memory T lymphocytes are significantly enriched in the CSF of patients with multiple sclerosis when compared with the peripheral blood of the same patients (Fig. 3D) , or to the CSF or peripheral blood of subjects with other neurological diseases. Since CSF-restricted oligoclonal bands are recognized as a surrogate marker of multiple sclerosis, we sought to establish whether MCAM expression correlates with the presence of oligoclonal bands. The percentage of MCAM + cells in peripheral blood CD4 + lymphocytes was found to be significantly higher among subjects with oligoclonal bands, compared with subjects without oligoclonal bands (Fig. 3E) .
To establish the histopathological relevance of MCAMexpressing T lymphocytes in multiple sclerosis, we studied MCAM expression in CNS lesions of patients with multiple sclerosis. We found an important upregulation of MCAM on the surface of infiltrated vessels in active multiple sclerosis lesions, compared with vessels in normal-appearing white matter and controls ( Fig. 3F and G) . MCAM is also co-expressed by IL17-producing cells and by CD4 + T lymphocytes in perivascular infiltrates in active multiple sclerosis lesions (Fig. 3H) , as well as by CD3 + T lymphocytes ( Supplementary Fig. 2 (Fig. 4A) . We then confirmed the importance of MCAM in the adhesion and transmigration of T H 17-polarized lymphocytes using an anti-MCAM monoclonal antibody. Treatment of endothelial cells with anti-MCAM antibody significantly increases the mean velocity of lymphocytes over resting or inflamed blood-brain barrier endothelial cells in a dynamic flow system (Fig. 4B) . Furthermore, using a modified Boyden chamber assay, we demonstrated that anti-MCAM antibody significantly reduces bloodbrain barrier transmigration of MCAM + lymphocytes, but not of MCAM À lymphocytes (Fig. 4C) . Finally, we observed MCAM enrichment at points of blood-brain barrier endothelial cell/lymphocyte interaction in vitro, in structures reminiscent of transmigratory cups (Fig. 4D) . Collectively, these data demonstrate that MCAM Fc-MCAM administration and depletion of MCAM + CD4 lymphocytes limit the severity of experimental autoimmune encephalomyelitis
In order to establish the importance of MCAM in CNS inflammation in vivo, we first confirmed expression of MCAM on mouse CNS endothelium and on infiltrating lymphocytes in the CNS of myelin oligodendrocyte glycoprotein (MOG) 35-55 -induced EAE animals. In these animals, MCAM is significantly upregulated on CNS vessels within normal-appearing white matter and lesions, as well as on CD4 + T lymphocytes derived from spleen/lymph node and CNS ( Supplementary Fig. 3A and B) , compared with nonimmunized control mice in which MCAM expression is barely detectable on lymphocytes. Moreover, expression of MCAM, as assessed by immunohistofluorescence stainings, is detected on IL17-expressing CNS-infiltrating lymphocytes in EAE (Fig. 5A) . We also confirmed that IL23 induces a strong upregulation of MCAM and of MCAM/IL7R on MOG 35-55 -reactivated murine lymphocytes ( Supplementary Fig. 3C and D) . Finally, the proportion of murine CD4 + T lymphocytes expressing IL17 and GM-CSF following in vitro reactivation was significantly higher in the MCAM + population than in the MCAM À population, while IFN expression was similar ( Supplementary Fig. 3E ), matching our human observations. Next, we elected to evaluate whether functional blockade of MCAM, using a chimeric human Fc-mouse MCAM fusion protein (Fc-MCAM), could impact on autoimmune neuroinflammation in vivo. Fc-MCAM injected intraperitoneally to EAE-affected animals was found to bind to CNS microvessels ( Supplementary Fig.  3F ). Administration of Fc-MCAM prior to the development of EAE symptoms significantly delayed EAE onset and reduced clinical severity of EAE, compared with control groups (PBS or isotype control; Fig. 5B ). Moreover, Fc-MCAM treatment significantly reduced the number and the area of demyelinating and infiltrated lesions, in both the brain and spinal cord of animals ( Fig. 5C and Supplementary Fig. 4 ). Fc-MCAM treatment also decreased the number of CD4, F4/80 or MHCII-expressing cells in the CNS of EAE mice sacrificed 15 days post-immunization ( Fig. 5D and E) . Although T lymphocyte activation in the peripheral compartment was not impaired in Fc-MCAM-treated animals (Fig. 5F ), the percentage of lymphocytes expressing IL17 was significantly lower in the CNS of Fc-MCAM-treated EAE-affected animals at 15 days post-immunization as assessed by flow cytometry (Fig. 5G-H 1.6 Â 10 5 AE 9 Â 10 3 IL17 + lymphocytes, n = 4 animals/condition) and did not impact on cell proliferation in vitro ( Supplementary  Fig. 3G ). Of clinical relevance, therapeutic administration of the Fc-MCAM after the onset of EAE (11 days post-immunization) significantly improved the clinical course of the disease (Fig. 5I ) compared with isotype control-treated animals. lymphocytes sorted ex vivo and activated with anti-CD3/CD28 and IL23 for 6 days. Cytokine production was assessed by flow cytometry. n = 3 donors. *P 5 0.05; **P 5 0.01, ***P 5 0.001; ns = not significant. n = 24), benign multiple sclerosis (benign; n = 4), clinically isolated syndrome suggestive of multiple sclerosis (CIS; n = 13), untreated relapsing-remitting (stable) patients with multiple sclerosis (RRMS; n = 27), acutely relapsing-remitting multiple sclerosis (relapse; n = 9), MCAM in multiple sclerosis MCAM depletion resulted in a significantly delayed and milder EAE course (Fig. 5J) . Moreover, absolute numbers of IL17 + and IL17 + /IFN + double-positive lymphocytes were similar in the spleen and lymph nodes, but significantly lower in the CNS of MCAM-depleted recipient animals, compared with non-depleted recipient animals (10 days post-transfer; Fig. 5K and L) . Altogether, these data demonstrate that MCAM is an important contributor to neuroinflammatory processes in vivo and that blockade of MCAM or depletion of MCAM + T lymphocytes reduce both the clinical severity of EAE and the pathological determinants of disease by limiting infiltration of IL17 + and IL17 + /IFN + T lymphocytes into the CNS, without impacting on lymphocyte activation in the peripheral compartment.
Discussion
In this report, we describe the role and function of MCAM in neuroinflammatory reactions. In healthy subjects, MCAM is expressed by blood-brain barrier endothelial cells and by a discrete subset of memory CD4 + T lymphocytes in response to IL23 stimu- We report here that human blood-brain barrier endothelial cells in primary culture express MCAM, as previously reported for human umbilical vascular endothelial cells (Bardin et al., 2009) . We further establish a strong association between the expression of MCAM and that of several markers associated with the T H 17 lineage including the surface markers CD161 and CCR6 (Cosmi et al., 2008; Dagur et al., 2011) . (Xie et al., 1997; Mills et al., 2002; Bu et al., 2006) , by demonstrating MCAM preferential expression on CD147 (extracellular matrix metalloproteinase inducer)-expressing cells . Recent fate-mapping studies of T H 17 lymphocytes indicate that most IFN-producing T lymphocytes present in EAE infiltrates are ex-T H 17, suggesting that CD4 + T lymphocytes are more plastic than previously recognized (Hirota et al., 2011) . While the exact role of IL17 in multiple sclerosis and EAE is still unclear, IL23 and its receptor are essential for CNS autoimmune inflammation (Langrish et al., 2005) and transfer of T H 17 lymphocytes generated in the presence of IL23 (compared with TGF-b) results in a more severe EAE course (Ghoreschi et al., 2010) . In humans, we have previously reported the induction of IFN-expressing and granzyme B-expressing T H 17 lymphocytes upon IL23 stimulation and their preferential recruitment in multiple sclerosis brains ). More recently, IL23, in part through ROR-, was shown to drive the production of GM-CSF, an essential factor for EAE induction (Ponomarev et al., 2007; Kroenke et al., 2010; Codarri et al., 2011; El-Behi et al., 2011) (Matusevicius et al., 1999; Frisullo et al., 2008; Brucklacher-Waldert et al., 2009; Durelli et al., 2009; Alexander et al., 2010; Babaloo et al., 2010; Li et al., 2011) . IL23 is also elevated in the peripheral blood of patients with multiple sclerosis (Krakauer et al., 2008; Alexander et al., 2010; Li et al., 2011) . In accordance with these data, we report a significantly higher proportion of MCAM-expressing CD4 + and CD4 + CD45RO + lymphocytes in the peripheral blood and CSF of patients with multiple sclerosis, compared with healthy controls and subjects with other neurological diseases. Most strikingly, MCAM expression was higher in patients in acute relapse but lower in patients under treatment, suggesting an association of lymphocyte-expressed MCAM with the inflammatory phase of the disease. Moreover, we show that MCAM is also expressed at the level of the blood-brain barrier in the healthy CNS, and that MCAM is strongly up-regulated on blood-brain barrier endothelial cells in active multiple sclerosis lesions. Furthermore, we provide strong evidence showing that MCAM is expressed by IL17-producing lymphocytes in perivascular immune infiltrates of active multiple sclerosis and EAE lesions. Expression of MCAM was previously reported on leukocytes within synovial effusions from arthritis patients (Dagur et al., 2010) and on peripheral blood mononuclear cells from patients suffering Behç et's disease, sarcoidosis, Crohn's disease (Dagur et al., 2011) and psoriasis (Kamiyama et al., 2012) . Our study provides novel evidence in the context of multiple sclerosis and EAE supporting a crucial role of MCAM in organ-targeted inflammatory processes. MCAM has been implicated in melanoma cell invasiveness and migration across endothelial cells (Xie et al., 1997; Mills et al., 2002; Bardin et al., 2009) . In addition to being a cell surface marker for a highly inflammatory T lymphocyte subset, our study demonstrates that MCAM is an adhesion molecule involved in the migration of these lymphocytes to the CNS. First, we confirm that MCAM participates in the adhesion of human T H 17 lymphocytes to primary cultures of human blood-brain barrier endothelial cells (Brucklacher-Waldert et al., 2009 ). We further demonstrate that MCAM blockade restricts T H 17 lymphocyte migration across blood-brain barrier endothelial cells in vitro and reduces infiltration of IL17-producing cells in the CNS of EAE animals in vivo. In addition, we show that Fc-MCAM provides therapeutic protection even when administered after the onset of EAE, suggesting that blocking the recruitment of encephalitogenic T lymphocytes after disease onset could be beneficial, at least in EAE, and possibly in multiple sclerosis. Although speculative, we postulate that the Fc-MCAM in vivo binds to endothelial cell-expressed MCAM or to any additional unidentified ligand of MCAM, as suggested by Bardin et al. (2009) , and impact on the interaction of MCAM with its ligand(s). Finally, we provide strong evidence that depletion of MCAM + lymphocytes reduces the severity of EAE and the entry of IL17 + and IL17 + /IFN + lymphocytes in the CNS, confirming that MCAM expression identifies CD4 + T lymphocytes with a significant encephalitogenic potential.
MCAM shows both homotypic (Staquicini et al., 2008) and heterotypic interactions with a yet unknown ligand(s) (Bardin et al., 2009) . Since both blood-brain barrier endothelial cells and pro-inflammatory lymphocytes express MCAM, MCAM-MCAM and MCAM-heterotypic ligand interactions could be relevant for lymphocytes infiltration into the CNS, and would warrant further studies. Our data provide strong evidence that MCAM is implicated in IL17 + and IL17 + /IFN + T lymphocytes migration across bloodbrain barrier endothelial cells, regardless of the type of interaction (homotypic, heterotypic or both). We cannot exclude the possibility that MCAM blockade reduces the severity of EAE by affecting other cell subsets in addition to T H 17 lymphocytes, especially as a small subset of mature natural killer cells also expresses MCAM in mice Despoix et al., 2008) . However, the presence of IL17-producing CD4 + MCAM + T lymphocytes in immune cell infiltrates of EAE animals, as well as the significant reduction in the number of IL17-producing cells in: (i) the CNS of MCAM-depleted CD4 + T lymphocytes recipient mice; and (ii) the CNS of mice treated with Fc-MCAM blocker demonstrate that MCAM is an important molecular determinant of IL17-expressing lymphocytes migration to the CNS in vivo. We postulate that the decreased number of CNS-infiltrating F4/80 macrophages, MHCII + and the possible accumulation of IFN-producing CD3 + T lymphocytes in peripheral lymphoid organs of Fc-MCAM-treated animals are consequences of the reduced accumulation in the CNS of IL17-and IL22-secreting cells, as these cytokines were previously shown to modulate bloodbrain barrier permeability and immune cell recruitment to the CNS (Kebir et al., 2007) .
Overall, our data demonstrate that MCAM is expressed by CNS endothelial cells and represents a marker of peripheral effector memory T lymphocytes that have the potential to secrete IL17, IL22, granzyme B and GM-CSF, in addition to IFN, in response to IL23 activation. MCAM is, to our knowledge, the first adhesion molecule involved in leukocyte homing and diapedesis whose expression is associated with a specific pro-inflammatory T lymphocyte subset. In that regard, as this adhesion molecule is specifically expressed by a lymphocyte subset with encephalitogenic capacity, blocking MCAM, or removing MCAM + cells from the circulation, could provide therapeutic benefit without causing CNS immunosuppression, such as seen with VLA-4 blockers. Moreover, MCAM presents the advantage of being a reliable and stable surface marker of circulating IL17 + and IL17 + /IFN + lymphocytes, a potential biomarker of multiple sclerosis disease and a novel therapeutic strategy to efficiently target the highly inflammatory subset of memory T lymphocytes, by either depleting them in the periphery or by restricting their entry into target organs, such as the CNS. animal, in two to three independent experiments. ns = not significant, *P 5 0.05, **P 5 0.01, ***P 5 0.001.
